D. Boral Capital Reiterates Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $21.00 target price on the stock.

Several other research firms have also recently weighed in on TRVI. EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Raymond James started coverage on Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 price objective for the company. Leerink Partners started coverage on Trevi Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Friday, November 8th. Finally, Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Trevi Therapeutics has a consensus rating of “Buy” and an average target price of $9.13.

Trevi Therapeutics Price Performance

Shares of NASDAQ:TRVI opened at $2.60 on Wednesday. The stock’s 50-day moving average is $3.00 and its 200 day moving average is $2.91. The company has a market cap of $199.85 million, a PE ratio of -5.91 and a beta of 0.96. Trevi Therapeutics has a 1 year low of $1.03 and a 1 year high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period last year, the firm posted ($0.08) earnings per share. Analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in Trevi Therapeutics by 180.8% during the 3rd quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after buying an additional 61,317 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Trevi Therapeutics by 10.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after purchasing an additional 117,418 shares in the last quarter. State Street Corp increased its holdings in shares of Trevi Therapeutics by 5.9% in the 3rd quarter. State Street Corp now owns 952,912 shares of the company’s stock worth $3,183,000 after purchasing an additional 53,051 shares in the last quarter. Fred Alger Management LLC bought a new stake in shares of Trevi Therapeutics in the 3rd quarter worth $256,000. Finally, Acuta Capital Partners LLC increased its holdings in shares of Trevi Therapeutics by 11.7% in the 3rd quarter. Acuta Capital Partners LLC now owns 290,500 shares of the company’s stock worth $970,000 after purchasing an additional 30,500 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.